Evaluation of the In Vitro Activity of Eravacycline against a Broad Spectrum of Recent Clinical Anaerobic Isolates | Zendy

David R. Snydman | Zendy; L. A. McDermott | Zendy; N V Jacobus | Zendy; Kathryn O. Kerstein | Zendy; Trudy H. Grossman | Zendy; Joyce A. Sutcliffe | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Evaluation of the In Vitro Activity of Eravacycline against a Broad Spectrum of Recent Clinical Anaerobic Isolates

Author(s) -

David R. Snydman,

L. A. McDermott,

N V Jacobus,

Kathryn O. Kerstein,

Trudy H. Grossman,

Joyce A. Sutcliffe

Publication year - 2018

Publication title -

antimicrobial agents and chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.07

H-Index - 259

eISSN - 1070-6283

pISSN - 0066-4804

DOI - 10.1128/aac.02206-17

Subject(s) - microbiology and biotechnology , biology , antibiotics , tigecycline , clostridium difficile , anaerobic bacteria , tetracycline , multiple drug resistance , bacteroides , bacteria , genetics

The novel fluorocycline antibiotic eravacycline is in development for use in the treatment of serious infections caused by susceptible and multidrug-resistant (MDR) aerobic and anaerobic Gram-negative and Gram-positive pathogens. Eravacycline and 11 comparator antibiotics were tested against recent anaerobic clinical isolates, including MDRBacteroides spp. andClostridium difficile . Eravacycline was potentin vitro against all the isolates tested, including strains with tetracycline-specific resistance determinants and MDR anaerobic pathogens resistant to carbapenems and/or β-lactam–β-lactamase inhibitor combinations.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research